CASPR plans $13.3 million semaglutide trial in alcohol and opioid use disorder

The wire

1. 01The Center for Addiction Science, Policy and Research and the Allegheny County Department of Human Services are preparing a $13.3 million randomized controlled trial of weekly semaglutide as an add-on to usual addiction care.
2. 02Endpoints extend beyond substance use to criminal-justice involvement, employment, health and housing, a broader outcome set than most incretin addiction studies.
3. 03The trial has not yet launched and no enrollment target, dosing schedule or readout date has been reported; prior GLP-1 addiction data remain small and mixed.

From the source

Major trial seeks to test semaglutide on adults with alcohol and opioid use disorder

The Center for Addiction Science, Policy and Research (CASPR) and the Allegheny County Department of Human Services are preparing to launch a major $13.3 million randomized controlled trial to test whether weekly semaglutide, as an additional support to existing care, can reduce alcohol and opioid use and reduce criminal-justice involvement while improving employment, health, and housing outcomes